DUBLIN--(BUSINESS WIRE)--The "The 2019 Worldwide Market for Targeted Cancer Therapeutics" report has been added to ResearchAndMarkets.com's offering.
The 2019 Worldwide Market for Targeted Cancer Therapeutics focuses on the expanding area of targeted therapies and includes current products available and discusses some of the most exciting developments in progress.
This report covers targeted cancer therapies that do at least one of the following:
- Block or turn off chemical signals that tell the cancer cell to grow and divide
- Change proteins within the cancer cells so the cells die
- Stop making new blood vessels to feed the cancer cells
- Trigger the immune system to kill the cancer cells
- Carry toxins to the cancer cells to kill them, but not normal cells
This report on the targeted cancer therapeutics market specifically focuses on five leading segments of targeted therapies - monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, CDK inhibitors, and proteasome inhibitors - providing information on a global level, including:
- Global Targeted Cancer Therapeutic Market Size and Forecast, 2010-2025 ($millions) (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, others)
- Cancer Monoclonal Antibody Market, 2018-2025 ($ millions)
- Top 10 Cancer Indicated Monoclonal Antibodies, 2017 and 2018 Sales (millions $)
- Monoclonal Antibodies in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
- Tyrosine Kinase Inhibitor Market, 2018-2025 ($ millions)
- Top 10 Cancer Indicated Tyrosine Kinase Inhibitors, 2017 and 2018 Sales (millions $)
- Tyrosine Kinase Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
- Angiogenesis Inhibitor Market, 2018-2025 ($ millions)
- Angiogenesis Inhibitors in Cancer Therapy (Trade Name, Biological Name, Indication[s])
- CDK Inhibitor Market, 2018-2025: ($ millions)
- CDK Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
- Proteasome Inhibitor Market, 2018-2025: ($ millions)
- Proteasome Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
- Other Targeted Therapies Market, 2018-2025: ($ millions)
- Other Targeted Cancer Therapies (Classification, Trade Name, Biological Name, Target, Indication[s])
The report also provides specific information by type and by target on a global level for the monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKI) segments, including:
The report includes competitive summaries of the leading market providers. In addition, the report provides competitor market share in major market segments, including:
- Cancer Monoclonal Antibody Competitor Market Share - Top Seven, 2018 ($ millions)
- Cancer TKI Competitor Market Share, 2018 ($ millions)
- Cancer CDK Inhibitors Competitor Market Share, 2018 ($ millions)
- Cancer Proteasome Inhibitor Competitor Market Share, 2018 ($ millions)
The 2019 Worldwide Market for Targeted Cancer Therapeutics concludes with profiles of the leading competitors in the targeted cancer therapeutic market, including:
- AbbVie, Inc.
- Advantagene, Inc.
- Agenus, Inc.
- Apollomics, Inc.
- Aptevo Therapeutics
- Celgene Corporation
- Celldex Therapeutics
- Celltrion, Inc.
- Celsion Corporation
- Clovis Oncology, Inc.
- Cold Genesys, Inc.
- Dendreon Pharmaceuticals LLC
- Eisai Co., Ltd.
- Eli Lilly & Company
- EMD Serono, Inc. (Merck KgaA)
- Inovio Pharmaceuticals, Inc.
- Johnson & Johnson
- MacroGenics, Inc.
- Merck & Co., Inc.
- Merrimack Pharmaceuticals, Inc.
- Nascent Biotech
- Northwest Biotherapeutics, Inc.
- Novartis AG
- Oncolytics Biotech, Inc.
- OncoMed Pharmaceuticals, Inc.
- OncoSec Medical, Inc.
- Oncternal Therapeutics
- Otsuka Holdings Co., Ltd.
- Pfizer, Inc.
- Puma Biotechnology, Inc.
- Seattle Genetics, Inc.
- Sesen Bio
- TG Therapeutics, Inc.
- Tocagen, Inc.
- Vascular Biogenics Ltd.
- ZIOPHARM Oncology, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/e2mjo6
